GENITAL WARTS MARKET RESEARCH REPORT, INDUSTRTY TRENDS AND FORECAST 2030

(Albany, US) DelveInsight has launched a new report on Genital Warts Market Insights, Epidemiology and Market Forecast-2030.

DelveInsight’s ‘Genital Warts (GWs) – Market Insights, Epidemiology and Market Forecast-2030 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of GWs in the United States.

 

Some of the key facts of the Report:

1. HPV 6 and 11 cause greater than 90% of genital warts cases in males and females.
2. Approximately 3–4 million cases of genital warts in men occur each year with a peak rate of 500 per 100,000 in the 25–29 year old group.
3. The incidence rate of GWs among all men in the study was 2.35 cases per 1000 person-years, with the highest incidence of 3.43 cases per 1000 person-years observed among men aged 18–30 years.

Key benefits of the Report

1. Genital Warts market report covers a descriptive overview and comprehensive insight of the Genital Warts epidemiology and Genital Warts market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Genital Warts market report provides insights on the current and emerging therapies.
3. Genital Warts market report offers a global historical and forecasted market covering drug outreach in 7 MM.
4. Genital Warts market report provides an edge that will help in developing business strategies by understanding trends shaping and driving the Genital Warts market.

 

Request for Sample Pages: https://www.delveinsight.com/sample-request/genital-warts-market

 

“According to DelveInsight’s analysis, majority of the cases of Genital warts are caused by HPV 6 and HPV 11 strains.”

Genital warts are small fleshy growths, bumps or skin changes that appear on or around the genital or anal area. These are the result of a viral skin infection caused by the human papilloma virus (HPV). They are usually painless and do not pose a serious threat to health.

Genital warts are spread through sexual intercourse, so they are classified as a sexually transmitted disease (STD), and can affect both men and women. They are also are known as condyloma acuminata or venereal warts. They can develop anywhere near the vagina, cervix, genitals or rectum.

Although around 30 different types of HPV can affect the genital skin, most cases of infection with HPV cause no visible symptoms. Around majority of all cases of genital warts are caused by two strains of the virus, i.e., type 6 and type 11.

Genital warts are transmitted through sexual activity, including oral, vaginal, and anal sex. The person may not start to develop warts for several weeks or months after infection. Genital warts are not always visible to the human eye. They may be very small and the color of the skin or slightly darker. The top of the growths may resemble a cauliflower and may feel smooth or slightly bumpy to the touch. They may occur as a cluster of warts, or just one wart.

In females, warts may appear around the vulva (entire outer female genital area), in or around the vagina, in or around the anus, the groin (where the genital area meets the inner thigh),or the cervix (although this is less common than external warts). In males, warts may appear on the penis, scrotum (balls), in or around the anus, or the groin area.

There is no cure for HPV, but genital warts can be removed. There are special, prescription-only treatments for genital warts. If left untreated, genital warts may go away, stay the same, or grow in size and number. For the prevention of the disease, the Food and Drug Administration (FDA) approved several HPV vaccine for people ages 9 through 45. The HPV vaccine protects against HPV types that cause most genital warts and most cervical cancers.

Some of the key companies working on Genital Warts are:

• Verrica Pharmaceuticals
• Cassiopea
• Xiamen Innovax Biotech
• Merck & Co.
• Allergan
• And Many Others.

The launch of the emerging therapies is expected to significantly impact the Genital Warts treatment scenario in the upcoming years:-

 Drugs Covered:

• VP-102
• CB-06-02
• HPV type 6/11 bivalent vaccine
• Condylox
• GARDASIL
• And Many Others.

 

Request a Free Sample Report:  https://www.delveinsight.com/sample-request/genital-warts-market

 

Table Of Conents:

1. Key Insights
2. Executive Summary of Genital Warts
3. Genital Warts Market Overview at a Glance

3.1. Market Share (%) Distribution of Genital Warts in 2017

3.2. Market Share (%) Distribution of Genital Warts in 2030

4. Disease Background and Overview: Genital Warts

4.1. Introduction

4.2. Causes

4.3. Signs and Symptoms

4.4. Developmental and Clinical Aspects of Genital Warts

4.5. Genetics of Genital Warts

4.6. Pathophysiology

4.7. Clinical manifestations in Genital Warts

4.8. Diagnosis

5. Epidemiology and Patient Population

5.1.1. Assumptions and Rationale

5.1.2. Total Incident Cases of Genital Warts in the United States (2017–2030)

5.1.3. Gender-specific Incident Cases of Genital Warts in the United States (2017–2030)

5.1.4. Age-specific Incident Cases of Genital Warts in the United States (2017–2030)

5.1.5. Incident Cases of Genital Warts by HPV strain type in the United States (2017–2030)

5.1.6. Treatable cases of Genital Warts in the United States (2017–2030)

6. Treatment
7. Unmet Needs
8. Marketed Drugs

8.1. Key Cross Competition

8.2. Condylox: Allergan

8.2.1. Product Description

8.2.2. Other Development Activities

8.2.3. Clinical Development

8.2.4. Product Profile

8.3. GARDASIL 9: Merck & Co.

8.3.1. Product Description

8.3.2. Other Developmental Activities

8.3.3. Clinical Development

8.3.4. Product Profile

To be continue in the report….

9. Emerging Therapies

Key Cross Competition

9.1. VP-102: Verrica Pharmaceuticals

9.1.1. Product Description

9.1.2. Other Development Activities

9.1.3. Clinical Development

9.1.4. Product Profile

9.2. CB-06-02: Cassiopea

9.2.1. Product Description

9.2.2. Other Development Activities

9.2.3. Clinical Development

9.2.4. Product Profile

9.3. HPV type 6/11 bivalent vaccine: Xiamen Innovax Biotech

9.3.1. Product Description

9.3.2. Other Development Activities

9.3.3. Clinical Development

9.3.4. Product Profile

To be continue in the report….

10. The United States Market Outlook

10.1. Total market size of Genital Warts in the United States

10.2. Therapeutic market size of Genital Warts in the United States

10.3. Prophylactic market size of Genital Warts in the United States

10.4. Market Size Genital Warts by Therapies

11. Market Drivers
12. Market Barriers
13. Appendix

13.1 Report Methodology

14. DelveInsight Capabilities
15. Disclaimer
16. About DelveInsight

 

Request a Free Sample Report:  https://www.delveinsight.com/sample-request/genital-warts-market